All Articles

After 15 years and 41 straight profitable quarters, PubMatic's CFO Steve Pantelick is retiring. A deep dive into his legacy and the ad tech firm's future.

Q2 results show growth, but rising costs and heavy spending underscore the pressure on Granite Ridge to hit its 2027 free cash flow inflection point.

APC's solid Q2 earnings are just half the story. A massive $235M acquisition in the Great Lakes signals a bold new phase of growth and consolidation.

A quiet revolution, mandated by the DoD, is dismantling the old guard of space acquisition. The move to modular systems is a strategic overhaul aimed at slashing costs, boosting innovation, and ensuring dominance in orbit.

Ad tech firm PubMatic stuns Wall Street with a major Q2 comeback, as its AI platform and CTV focus drive an 11% revenue surge and expanded profits.

PAR Technology's Q2 results reveal soaring profitability and 19% revenue growth, prompting a raised 2026 outlook fueled by its AI-driven platform.

Resmed posts record revenue and boosts shareholder returns, but its strategic pivot and operational hurdles reveal a more complex story of medtech leadership.

Twilio's stellar Q2 results boast record profits, but the real story lies in its AI-powered strategic shift, driving strong organic growth and future-proofing its platform.

iRhythm's stellar Q2 results are just the start. A major acquisition and a new AI algorithm are set to reshape the cardiac monitoring landscape.

The software supply chain firm's Q2 results beat estimates, with cloud revenue soaring 53% as its security platform becomes essential for the AI era.

With a $250M decision pending and a major acquisition closing, Zymeworks is betting its future on a radical pivot to a diversified, revenue-generating model.

electroCore posts strong Q2 growth and raises guidance, driven by a federal market focus. But as the company maps a path to profitability, a closer look reveals a race between strategic execution and a dwindling cash runway.

After two years of losses, Silvaco is back in the black. A deep dive into the AI strategy and key partnerships with NVIDIA, Micron, and Dassault driving its comeback.

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

Kodiak AI posts strong Q2 growth and unveils its Gen7 platform, accelerating its push for driverless long-haul. But can revenue outpace a steep cash burn?

NATR's Q2 results show a firm investing heavily in its digital future, with soaring e-commerce sales and subscription growth offsetting currency and China woes.

Octave Specialty Group's core insurance unit saw 77% revenue growth, fueled by strategic buys and a new AI underwriting platform that signals a tech-led future.

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

Beyond the mixed GAAP results, ICU Medical’s strong non-GAAP growth and raised guidance reveal a company thriving after a strategic pivot.

Artiva Biotherapeutics secures FDA fast-track status for its novel NK cell therapy, AlloNK. This could revolutionize autoimmune care for millions.